Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) saw unusually-high trading volume on Wednesday . Approximately 1,456,233 shares changed hands during trading, an increase of 612% from the previous session’s volume of 204,515 shares.The stock last traded at $6.00 and had previously closed at $4.87.
DFFN has been the topic of a number of recent research reports. ValuEngine lowered shares of Diffusion Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, February 2nd. HC Wainwright set a $15.00 price target on shares of Diffusion Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 15th.
The stock has a market capitalization of $18.03 million, a P/E ratio of -0.28 and a beta of 0.27.
An institutional investor recently bought a new position in Diffusion Pharmaceuticals stock. Two Sigma Investments LP acquired a new position in shares of Diffusion Pharmaceuticals Inc (NASDAQ:DFFN) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 32,176 shares of the company’s stock, valued at approximately $64,000. Two Sigma Investments LP owned approximately 0.95% of Diffusion Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 6.24% of the company’s stock.
Diffusion Pharmaceuticals Company Profile (NASDAQ:DFFN)
Diffusion Pharmaceuticals Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer. Its lead product candidate is transcrocetinate sodium, which has initiated Phase 3 trials for the treatment of glioblastoma multiforme (GBM); Phase 2 clinical trials for the treatment of pancreatic cancer; Phase 2/3 clinical trials for the treatment of metastatic brain cancer; and Phase 2 trial for the treatment of stroke.
Featured Article: Growth Stocks, What They Are, What They Are Not
Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.